Biography:Taofeek Owonikoko
 | This article may rely excessively on sources too closely associated with the subject, potentially preventing the article from being verifiable and neutral. (June 2020) (Learn how and when to remove this template message) |
Taofeek Kunle Owonikoko | |
|---|---|
| Born | Nigeria |
| Alma mater |
|
| Scientific career | |
| Institutions | Emory University Johns Hopkins University |
| Thesis | Genetische Heterogenität in Adenokarzinomen des Ösophagus (2000) |
Taofeek Kunle Owonikoko is an American physician who is Professor and Vice-Chair for Faculty Development, Department of Haematology and Medical Oncology at the Winship Cancer Institute. His research considers small cell lung cancer. He was a 2019 Emory University Woodruff Leadership Academy Fellow.
Early life and education
Owonikoko is from Nigeria. He attended the Obafemi Awolowo University, where he specialised in medicine.[citation needed] Owonikoko completed his residency at the Lagos University Teaching Hospital. In 1998 he was awarded a German research fellowship to join Heinrich Heine University Düsseldorf.[citation needed] Whilst in Germany Owonikoko earned a doctoral degree in anatomical pathology.[1]
Research and career
In 2001 Owonikoko joined Johns Hopkins University as a postdoctoral fellow, where he worked in molecular imaging.[2] Owonikoko was designated as a Distinguished Cancer Scholar in the Georgia Cancer Coalition in 2008. That year he joined Emory University as an Associate Professor.[3]
He specialises in small cell lung cancer.[citation needed] He leads clinical trials into novel immunotherapy drugs, which can be used to treat aggressive and recurrent cancers.[4] He has studied the efficacy of talazoparib as a treatment for small cell lung cancer patients with homologous recombination repair deficiency.[5]
Owonikoko has called for more people of color to be involved with clinical cancer trials.[6] In particular, Black patients are below 4% of patients involved in clinical trials for lung cancer.[6] He believes that this underrepresentation perpetuates healthcare outcome inequality.[6]
Awards and honours
- 2008 Who's Who[7]
- 2016 National Cancer Institute Cancer Clinical Investigator Team Leadership Award[8]
- 2019 Emory University Woodruff Leadership Academy Fellow[9]
Selected publications
- Owonikoko, Taofeek K.; Ragin, Camille C.; Belani, Chandra P.; Oton, Ana B.; Gooding, William E.; Taioli, Emanuela; Ramalingam, Suresh S. (2007-12-10). "Lung Cancer in Elderly Patients: An Analysis of the Surveillance, Epidemiology, and End Results Database" (in en). Journal of Clinical Oncology 25 (35): 5570–5577. doi:10.1200/JCO.2007.12.5435. ISSN 0732-183X. PMID 18065729.
- Ramalingam, Suresh S.; Owonikoko, Taofeek K.; Khuri, Fadlo R. (2011-03-08). "Lung cancer: New biological insights and recent therapeutic advances" (in en). CA: A Cancer Journal for Clinicians 61 (2): 91–112. doi:10.3322/caac.20102. PMID 21303969. http://doi.wiley.com/10.3322/caac.20102.
- Owonikoko, Taofeek Kunle; Hussain, Arif; Stadler, Walter Michael; Smith, David C.; Kluger, Harriet; Molina, Ana M.; Gulati, Parul; Shah, Aadhar et al. (2016). "First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70" (in en). Cancer Chemotherapy and Pharmacology 77 (1): 155–162. doi:10.1007/s00280-015-2909-2. ISSN 0344-5704. PMID 26576779. http://link.springer.com/10.1007/s00280-015-2909-2.
References
- ↑ Owonikoko, Taofeek Kunle (2000). Genetische Heterogenität in Adenokarzinomen des Ösophagus (Barrettkarzinom) (Thesis). Düsseldorf. OCLC 1106722001.
- ↑ "Taofeek Owonikoko, MD, PhD, MSCR". https://winshipcancer.emory.edu/%0A%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20/bios/faculty/owonikoko-taofeek.
- ↑ "PRIME® Faculty Biography - Taofeek Owonikoko, MD, PhD, MSCR" (in en). https://primeinc.org/.
- ↑ Worbel, Sylvia (2018). "Outpacing Cancer". https://www.emory.edu/EMORY_MAGAZINE/issues/2018/winter/features/outpacing-cancer/index.html.
- ↑ "You have been blocked". https://www.cancernetwork.com/view/dr-owonikoko-talazoparib-hrrd-positive-stage-iv-squamous-cell-lung-cancer.
- ↑ 6.0 6.1 6.2 Nazha, Bassel; Mishra, Manoj; Pentz, Rebecca; Owonikoko, Taofeek K. (2019-05-01). "Enrollment of Racial Minorities in Clinical Trials: Old Problem Assumes New Urgency in the Age of Immunotherapy". American Society of Clinical Oncology Educational Book 39 (39): 3–10. doi:10.1200/EDBK_100021. ISSN 1548-8748. PMID 31099618. https://ascopubs.org/doi/10.1200/EDBK_100021.
- ↑ (in English) Taofeek Kunle Owonikoko. OCLC 5974025329. https://www.worldcat.org/oclc/5974025329.
- ↑ "Owonikoko receives NCI Cancer Clinical Investigator Team Leadership Award" (in en). 2016-07-13. https://news.emory.edu/stories/2016/07/owonikoko_nci_cancer_clinical_investigator_award/index.html.
- ↑ "2019 Fellows". http://whsc.emory.edu/wla/members/2019/index.html.
 |  |
